Lonza Group AG Expands U.S. Presence Through Merck CDMO Acquisition

Lonza Group AG, the Swiss‑based life‑sciences tools and services provider listed on the SIX Swiss Exchange, announced on 3 November 2026 that it has acquired Merck KGaA’s contract development and manufacturing organization (CDMO) business in the United States. The transaction, reported by multiple news outlets—including Contract Pharma, Business Korea, Bionity, Pharmazeutische Zeitung, and Chemander Online—is a strategic move that positions Lonza to compete more directly with industry peers such as Samsung Biologics.

The acquisition consolidates Lonza’s already robust U.S. manufacturing footprint and expands its portfolio of biopharmaceutical development services. By integrating Merck’s U.S. CDMO facilities, Lonza will be able to offer a broader suite of contract manufacturing capabilities, from early‑stage formulation to commercial production, thereby strengthening its appeal to pharmaceutical, biotechnology, and nutrition clients.

Market Reaction

The news arrived just before the closing of the Swiss market on 4 November 2026. While the Swiss Market Index (SMI) ended that day on an upbeat note—recovering from a cautious opening and climbing higher as the session progressed—investors remained measured in the broader European and U.S. markets. In contrast, the U.S. stock market displayed a more subdued response, reflecting general caution among investors following a choppy session on 5 November 2026.

Lonza’s share price on 4 November 2026 closed at CHF 672.4, only marginally below the 52‑week high of CHF 674 recorded on the same day. The company’s market capitalization stands at CHF 51.84 billion, and its price‑earnings ratio of 44.04 indicates that investors are pricing in significant growth expectations from the expanded U.S. operations.

CEO Engagement at Jefferies Global Healthcare Conference

On 4 November 2026, Lonza’s chief executive officer, Wolfgang Wienand, was scheduled to present at the Jefferies Global Healthcare Conference in Basel, Switzerland (14:00 CET/CEST). The conference, a key gathering for industry stakeholders, offered Wienand a platform to discuss Lonza’s strategic direction, including the Merck CDMO acquisition, and to highlight the company’s commitment to advancing medical treatments through partnership and innovation.

Strategic Implications

By adding Merck’s U.S. CDMO capabilities, Lonza enhances its competitive positioning in several ways:

  1. Scale and Capacity – The acquisition increases manufacturing capacity, enabling Lonza to serve larger, more complex biologic projects and to respond more flexibly to client demand.
  2. Geographic Reach – A stronger U.S. presence allows Lonza to offer seamless, integrated services from development to commercial manufacturing across multiple regions.
  3. Technology Transfer – Merck’s established technologies and expertise in CDMO processes enrich Lonza’s portfolio, fostering cross‑pollination of best practices.
  4. Client Retention and Growth – Existing clients benefit from expanded service offerings, while new clients may be attracted to Lonza’s broadened capabilities, particularly in the competitive U.S. market where competitors such as Samsung Biologics are actively expanding.

Broader Industry Context

The acquisition comes at a time when the global surface disinfectant market is projected to reach US$ 7.5 billion by 2031, growing at a compound annual growth rate of 7.4 % (Wissen Research). While this statistic is not directly linked to Lonza’s core business, it underscores the broader health‑care and consumer‑goods sectors’ continued expansion—an environment that benefits companies offering advanced manufacturing services.

Conclusion

Lonza Group AG’s acquisition of Merck KGaA’s U.S. CDMO business marks a decisive step toward becoming a global leader in biopharmaceutical manufacturing. With the expanded U.S. footprint, enhanced service capabilities, and a clear strategic vision communicated by CEO Wolfgang Wienand at a prominent industry conference, Lonza is positioned to capitalize on the growing demand for high‑quality, scalable drug development and production services.